Tachykinin neurokinin 3 receptor antagonists: a patent review (2005 – 2010)

Bibliography

• Alexander SP, Mathie A, Peters JA. Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol 2008;153:S1-209
   Google Scholar
• Almeida TA, Rojo J, Nieto PM, Tachykinins and tachykinin receptors: structure and activity relationships. Curr Med Chem 2004;21:2045-81
   Web of Science ®Google Scholar
• Beaujouan JC, Torrens Y, Saffroy M, A 25 year adventure in the field of tachykinins. Peptides 2004;25:339-57
   PubMed Web of Science ®Google Scholar
• Severini C, Improta G, Falconieri-Erspamer G, The tachykinin peptide family. Pharmacol Rev 2002;54:285-322
   PubMed Web of Science ®Google Scholar
• Sarau HM, Griswold DE, Potts W, Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist. J Pharmacol Exp Ther 1997;281:1303-11
   PubMed Web of Science ®Google Scholar
• Emonds-Alt X, Bichon D, Ducoux JP, SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor. Life Sci 1995;56:PL27-32
   PubMed Web of Science ®Google Scholar
• Nguyen-Le XK, Nguyen QT, Gobeil F, Pharmacological characterization of SR 142801: a new non-peptide antagonist of the neurokinin NK-3 receptor. Pharmacology 1996;52:283-91
   PubMed Web of Science ®Google Scholar
• Giardina GA, Raveglia LF, Grugni M, Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412). J Med Chem 1999;42:1053-65
   PubMed Web of Science ®Google Scholar
• Langlois X, Wintmolders C, te Riele P, Detailed distribution of neurokinin 3 receptors in the rat, guinea pig and gerbil brain: a comparative autoradiographic study. Neuropharmacology 2001;40:242-53
   PubMed Web of Science ®Google Scholar
• Shughrue PJ, Lane MV, Merchenthaler I. In situ hybridization analysis of the distribution of neurokinin-3 mRNA in the rat central nervous system. J Comp Neurol 1996;372:395-414
   PubMed Web of Science ®Google Scholar
• Stoessl AJ. Localization of striatal and nigral tachykinin receptors in the rat. Brain Res 1994;646:13-18
   PubMed Web of Science ®Google Scholar
• Nagano M, Saitow F, Haneda E. Distribution and pharmacological characterization of primate NK-1 and NK-3 tachykinin receptors in the central nervous system of the rhesus monkey. Br J Pharmacol 2006;147:316-23
   PubMed Web of Science ®Google Scholar
• Chung FZ, Wu LH, Tian Y, Two classes of structurally different antagonists display similar species preference for the human tachykinin neurokinin3 receptor. Mol Pharmacol 1995;48:711-16
   PubMed Web of Science ®Google Scholar
• Leffler A, Ahlstedt I, Engberg S, Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3. Biochem Pharmacol 2009;77:1522-30
   PubMed Web of Science ®Google Scholar
• Meltzer H, Prus A. NK3 receptor antagonists for the treatment of schizophrenia. Drug Discov Today Ther Strat 2006;3:555-60
   Google Scholar
• Spooren W, Riemer C, Meltzer H. Opinion: NK3 receptor antagonists: the next generation of antipsychotics? Nat Rev Drug Discov 2005;4:967-75
   PubMed Web of Science ®Google Scholar
• Harrison PJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999;122:593-624
   PubMed Web of Science ®Google Scholar
• Marco N, Thirion A, Mons G, Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: an in vivo microdialysis approach in guinea pig. Neuropeptides 1998;32:481-8
   PubMed Web of Science ®Google Scholar
• Dawson LA, Cato KJ, Scott C, In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia. Neuropsychopharmacology 2008;33:1642-52
   PubMed Web of Science ®Google Scholar
• Nordquist RE, Delenclos M, Ballard TM, Cognitive performance in neurokinin 3 receptor knockout mice. Psychopharmacology (Berl) 2008;198:211-20
   PubMed Web of Science ®Google Scholar
• Evangelista S. Talnetant GlaxoSmithKline. Curr Opin Investig Drugs 2005;6:717-21
   PubMedGoogle Scholar
• Meltzer HY, Arvanitis L, Bauer D, Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 2004;161:975-84
   PubMed Web of Science ®Google Scholar
• Liem-Moolenaar M, Gray FA, de Visser SJ, Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol. J Psychopharmacol 2010;24:73-82
   PubMed Web of Science ®Google Scholar
• Dawson LA, Smith PW. Therapeutic utility of NK3 receptor antagonists for the treatment of schizophrenia. Curr Pharm Des 2010;16:344-57
   PubMed Web of Science ®Google Scholar
• Simonsen KB, Juhl K, Steiniger-Brach B, Novel NK(3) receptor antagonists for the treatment of schizophrenia and other CNS indications. Curr Opin Drug Discov Devel 2010;13:379-88
   PubMedGoogle Scholar
• Attwood TK. A compendium of specific motifs for diagnosing GPCR subtypes. Trends Pharmacol Sci 2001;22:162-5
   PubMed Web of Science ®Google Scholar
• Nygaard R, Frimurer TM, Holst B, Ligand binding and micro-switches in 7TM receptor structures. Trends Pharmacol Sci 2009;30:249-59
   PubMed Web of Science ®Google Scholar
• Palczewski K, Kumasaka T, Hori T, Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000;289:739-45
   PubMed Web of Science ®Google Scholar
• Malherbe P, Bissantz C, Marcuz A, Me-talnetant and osanetant interact within overlapping but not identical binding pockets in the human tachykinin neurokinin 3 receptor transmembrane domains. Mol Pharmacol 2008;73:1736-50
   PubMed Web of Science ®Google Scholar
• Malherbe P, Kratzeisen C, Marcuz A, Identification of a critical residue in the transmembrane domain 2 of tachykinin neurokinin 3 receptor affecting the dissociation kinetics and antagonism mode of osanetant (SR 142801) and piperidine-based structures. J Med Chem 2009;52:7103-12
   PubMed Web of Science ®Google Scholar
• Astrazeneca AB. Preparation of morpholinylazetidines as neurokinin receptor antagonists for treating gastrointestinal disorders. US270399; 2007
   Google Scholar
• Astrazeneca AB. Preparation of azetidine derivatives as neurokinin receptor antagonists for treatment of gastrointestinal diseases. WO137790; 2006
   Google Scholar
• Astrazeneca AB. Preparation of azetidine derivatives as neurokinin receptor antagonists for treatment of gastrointestinal diseases. WO137791; 2006
   Google Scholar
• Astrazeneca AB. Preparation of azetidinyl compounds as neurokinin antagonists for treating gastrointestinal disorder. WO136325; 2007
   Google Scholar
• Astrazeneca AB. Preparation of azetidinyl compounds as neurokinin antagonists for treating gastrointestinal disorder. US270400; 2007
   Google Scholar
• Astrazeneca AB. Azetidine compounds as neurokinin receptor antagonists, their preparation, pharmaceutical compositions, and use in therapy. WO037743; 2007
   Google Scholar
• Astrazeneca AB. Preparation of azetidinylpiperidine compounds as neurokinin antagonists for treating gastrointestinal disorders. WO136324; 2007
   Google Scholar
• Astrazeneca AB. Preparation of azetidinepiperazine derivatives as neurokinin receptor antagonists for treatment of gastrointestinal disorders. WO076042; 2008
   Google Scholar
• Astrazeneca AB. Preparation of cyanophenylethyl quinolinecarboxamides as neurokinin-3 (NK-3) receptor ligands. WO035157; 2007
   Google Scholar
• Astrazeneca AB. Amide substituted quinolines, processes for preparing them, pharmaceutical compositions containing them, and their use as modulators of neurokinin-3 (NK-3) receptors. WO086799; 2007
   Google Scholar
• Astrazeneca AB. Preparation of quinolinecarboxylic acid pyridinylamides as NK3 receptor modulators. WO018465; 2007
   Google Scholar
• Astrazeneca AB. Preparation of oxopyridyl quinoline amides as NK3 receptor modulators. WO018469; 2007
   Google Scholar
• Astrazeneca AB. Preparation of quinoline derivatives as NK3 antagonists. WO130080; 2006
   Google Scholar
• Astrazeneca AB. Preparation of quinolin-3-yl sulfonate esters as NK3 receptor modulators. WO137789; 2006
   Google Scholar
• Astrazeneca AB. Preparation of alkylpyridyl quinolines as NK3 receptor modulators. WO018466; 2007
   Google Scholar
• Astrazeneca AB. Preparation of 3-(aminomethyl)quinoline-4-carboxamide N-oxides as neurokinin-3 (NK-3) receptor ligands. WO035156; 2007
   Google Scholar
• Astrazeneca AB. Preparation of quinolinecarboxyamide derivatives for use as CNS agents. WO115140; 2008
   Google Scholar
• Astrazeneca AB. Preparation of alkyl sulfoxide quinolines as Nk-3 receptor ligands. WO035158; 2007
   Google Scholar
• Astrazeneca AB. Alkylsulphonamide quinolines. WO069977; 2007
   Google Scholar
• Simpson TR, Gadient R, Li Y, Discovery of AZD2624: a potent and selective NK3 antagonist to test the NK3 hypothesis in schizophrenia. Abstracts of Papers, 239th ACS National Meeting; 21 – 25 March 2010: MEDI-35; San Francisco, CA, USA
   Google Scholar
• SmithKline Beecham Corp. Preparation of 3-(piperazinylmethyl)-4-quinolinecarboxamides as NK2 and NK3 receptor antagonists. WO000247; 2005
   Google Scholar
• SmithKline Beecham Corp. Quinolinecarboxamides having activity at NK3 receptor and their preparations, pharmaceutical compositions and use for treatment of disease mediated by modulation of NK3 receptors. WO050992; 2006
   Google Scholar
• SmithKline Beecham Corp. Quinolinecarboxamides having activity at NK3 receptor and their preparations, pharmaceutical compositions and use for treatment of disease mediated by modulation of NK3 receptors. WO050991; 2006
   Google Scholar
• SmithKline Beecham Corp. Preparation of 4-quinolinecarboxamides useful for treatment of central nervous system diseases mediated by modulation of the NK3 receptor. WO050989; 2006
   Google Scholar
• SmithKline Beecham Corp. Preparation of quinoline-4-carboxamide derivatives as neurokinin 3 receptor antagonists. WO014575; 2005
   Google Scholar
• Smith PW, Wyman PA, Lovell P, New quinoline NK3 receptor antagonists with CNS activity. Bioorg Med Chem Lett 2009;19:837-40
   PubMed Web of Science ®Google Scholar
• Dawson LA, Langmead CJ, Dada A, In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. Eur J Pharmacol 2010;627:106-14
   PubMed Web of Science ®Google Scholar
• SmithKline Beecham Corp. Pyridine derivatives as NK receptor inhibitors and their preparation, pharmaceutical compositions, and use in the treatment of psychotic disorders. WO028654; 2007
   Google Scholar
• F. Hoffmann-La Roche AG. Preparation of 2-phenyl-N-(pyridin-3-yl)-N-methylisobutyramide derivatives as dual NK1/NK3 antagonists for treating schizophrenia. WO002577; 2005
   Google Scholar
• Peters J-U, Hoffmann T, Schnider P, Discovery of potent, balanced and orally active dual NK1/NK3 receptor ligands. Bioorg Med Chem Lett 2010;20(11):3405-8
   PubMed Web of Science ®Google Scholar
• SmithKline Beecham Corp. Preparation of crystalline forms of a pyridine derivative. WO015626; 2010
   Google Scholar
• Janssen Pharmaceutica NV. (2-Benzyl-4-{4-[1-(tetrahydrofuran-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-trifluoromethylphenyl))methanone for the treatment of schizophrenia. WO123081; 2005
   Google Scholar
• Janssen Pharmaceutica NV. Preparation of diaza-spiro-[5.5]-undecane derivatives as neurokinin antagonists. WO097795; 2005
   Google Scholar
• Janssen Pharmaceutica NV. Preparation of alkyl- and alkanoyl-piperazine derivatives as neurokinin antagonists. WO097774; 2005
   Google Scholar
• Janssen Pharmaceutica NV. Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their preparation, pharmaceutical compositions and their use as neurokinin antagonists. WO094934; 2006
   Google Scholar
• Janssen Pharmaceutica NV. Preparation of diaza-spiro-[4.5]-undecane derivatives as neurokinin antagonists. WO097794; 2005
   Google Scholar
• H. Lundbeck A/S. Preparation of 1-phenylcyclopropane-1-carboxamide derivatives as tachykinin NK3 receptor antagonists. WO016884; 2005
   Google Scholar
• H. Lundbeck A/S. Isoquinolinone derivatives as NK3 antagonists and their preparation, pharmaceutical compositions and use in the treatment of psychosis and schizophrenia. WO143402; 2009
   Google Scholar
• H. Lundbeck A/S. Preparation of isoquinolinone derivatives for use as NK3 antagonists. WO045948; 2010
   Google Scholar
• H. Lundbeck A/S. Isoquinolinone derivatives as NK3 antagonists for treatment of psychosis and schizophrenia. WO130240; 2009
   Google Scholar
• H. Lundbeck A/S. Isoquinolinone derivatives as NK3 antagonists and their preparation and use in the treatment of psychosis and schizophrenia. WO156339; 2009
   Google Scholar
• H. Lundbeck A/S. Preparation of isoquinolinone derivatives for use as NK3 antagonists. WO076016; 2010
   Google Scholar
• H. Lundbeck A/S. Preparation of isoquinolinone derivatives for use as NK3 antagonists. WO028655; 2010
   Google Scholar
• Merck Sharp & Dohme Ltd. Preparation of heterocyclylmethylquinolinecarboxamides as neurokinin receptor antagonists. WO012900; 2007
   Google Scholar
• Merck Sharp & Dohme Ltd. Preparation of substituted quinoline-4-carboxylic hydrazides as NK-2/NK-3 receptor ligands. WO072045; 2004
   Google Scholar
• Merck Sharp & Dohme Ltd. Preparation of quinoline-4-carboxylic acid hydrazides as neurokinin receptor antagonists with therapeutic uses. WO120478; 2006
   Google Scholar
• Elliott JM, Carling RW, Chambers M, N′,2-Diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists. Bioorg Med Chem Lett 2006;16:5748-51
   PubMed Web of Science ®Google Scholar
• Elliott JM, Carling RW, Chicchi GG, N′,2-Diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II. Bioorg Med Chem Lett 2006;16:5752-6
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme Ltd. Preparation of substituted cyclohexyl derivatives as Nk-3 receptor antagonists. WO003965; 2007
   Google Scholar
• Pfizer, Inc. Phenylpiperidines as NK1 and NK3 antagonists, their preparation, pharmaceutical compositions and use in the treatment of neurokinin-mediated diseases. WO256164; 2005
   Google Scholar
• F. Hoffmann-La Roche AG. Preparation of bistrifluoromethylphenylisobutyric acid pyridinylamides as dual tachykinin NK1/NK3 antagonists for treatment of schizophrenia. WO013050; 2006
   Google Scholar
• Hoffmann T, Bos M, Stadler H, Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists. Bioorg Med Chem Lett 2006;16:1362-5
   PubMed Web of Science ®Google Scholar
• F. Hoffmann-La Roche AG. Quinazoline derivatives as NK3 receptor antagonists and their preparation and use for the treatment of diseases. WO054968; 2010
   Google Scholar
• F. Hoffmann-La Roche AG. Piperazine and [1,4]-diazepan derivatives as neurokinin antagonists and their preparation. WO151969; 2008
   Google Scholar
• F. Hoffmann-La Roche AG. Preparation of piperidine derivatives as NK3 receptor antagonists. WO033995; 2009
   Google Scholar
• F. Hoffmann-La Roche AG. Preparation of spiropiperidine derivatives as antagonists of neurokinin 3 receptors. WO081012; 2008
   Google Scholar
• F. Hoffmann-La Roche AG. Preparation of prolinamide derivatives as NK3 antagonists. WO148689; 2008
   Google Scholar
• F. Hoffmann-La Roche AG. Preparation of prolinamide-tetrazole derivatives, particularly 1-[[(2S,4S)-4-(5-phenyl-2H-tetrazol-2-yl)pyrrolidin-2-yl]carbonyl]piperazines, as NK3 antagonists. WO148688; 2008
   Google Scholar
• F. Hoffmann-La Roche AG. Pyrrolidine derivatives as dual NK1/NK3 receptor antagonists and their preparation, pharmaceutical compositions and use in the treatment of schizophrenia. WO128891; 2008
   Google Scholar
• Ratni H, Ballard TM, Bissantz C, Rational design of novel pyrrolidine derivatives as orally active neurokinin-3 receptor antagonists. Bioorg Med Chem Lett 2010;20:6735-8
   PubMed Web of Science ®Google Scholar
• F. Hoffmann-La Roche AG. N-Benzyl pyrrolidinamine derivatives as NK-3 receptor antagonists and their preparation and use in the treatment of diseases. WO040663; 2010
   Google Scholar
• Hoffmann-La Roche AG. Preparation of N-benzyl pyrrolidinamine derivatives as neurokinin-3 receptor antagonists and their use in the treatment of diseases. WO113424; 2010
   Google Scholar
• F. Hoffmann-La Roche AG. Pyrrolidine-(hetero)aryl ether derivatives as NK3 receptor antagonists and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO019163; 2009
   Google Scholar
• F. Hoffmann-La Roche AG. Pyrrolidine aryl-ether as NK3 receptor antagonists, their preparation, and pharmaceutical applications. WO024502; 2009
   Google Scholar
• F. Hoffmann-La Roche AG. Preparation of pyridinyloxyethylpyrrolidinyl piperidinyl methanones and related compounds as neurokinin NK3 receptor antagonists. WO306043; 2009
   Google Scholar
• F. Hoffmann-La Roche AG. Preparation of phenylpiperidine derivatives for use as NK-3 receptor antagonists. WO086259; 2010
   Google Scholar
• F. Hoffmann-La Roche AG. Piperidine derivatives as nk3 receptor antagonists. WO106081; 2010
   Google Scholar
• Neurogen Corp. Preparation of diaryl imidazoles as neurokinin-3 receptor modulators. US148601; 2005
   Google Scholar
• Neurogen Corp. Preparation of diaryl pyrazoles as neurokinin-3 receptor modulators. WO061462; 2005
   Google Scholar
• Solvay Pharmaceuticals G.m.b.H. Piperidinamines as dual NK2/NK3-antagonists, pharmaceutical compositions comprising them and processes for their preparations and use in the treatment of diseasesWO088181; 2007
   Google Scholar
• Takeda Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds as tachykinin receptor antagonists and their preparation and use in the treatment of diseasesWO072643; 2009
   Google Scholar
• Takeda Pharmaceutical Co., Ltd. Preparation of nitrogen-containing heterocyclic compounds as tachykinin receptor antagonistsWO032856; 2010
   Google Scholar
• GSK. 2010; Available from: http://www.gsk.com/investors/product_pipeline/docs/GSK-product-pipeline-Feb-2010.pdf. [Cited]
   Google Scholar
• Krajewski SJ, Anderson MJ, Iles-Shih L, Morphologic evidence that neurokinin B modulates gonadotropin-releasing hormone secretion via neurokinin 3 receptors in the rat median eminence. J Comp Neurol 2005;489:372-86
   PubMed Web of Science ®Google Scholar
• Sandoval-Guzman T, Rance NE. Central injection of senktide, an NK3 receptor agonist, or neuropeptide Y inhibits LH secretion and induces different patterns of Fos expression in the rat hypothalamus. Brain Res 2004;1026:307-12
   PubMed Web of Science ®Google Scholar
• Topaloglu AK, Reimann F, Guclu M, TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction. Nat Genet 2009;41:354-8
   PubMed Web of Science ®Google Scholar
• Ramaswamy S, Seminara SB, Ali B, Neurokinin B stimulates GnRH release in the male monkey (Macaca mulatta) and is colocalized with kisspeptin in the arcuate nucleus. Endocrinology 2010;151:4494-503
   PubMed Web of Science ®Google Scholar
• SmithKline Beecham Corp. Anti-androgens and methods for treating disease. WO43008; 2000
   Google Scholar
• Schering Corp. The use of neurokinin receptor antagonists to treat androgen-dependent diseases. WO089802; 2002
   Google Scholar
• Losco PE, Leach MW, Sinha D, Administration of an antagonist of neurokinin receptors 1, 2, and 3 results in reproductive tract changes in beagle dogs, but not rats. Toxicol Pathol 2007;35:310-22
   Google Scholar
• Houghton LA, Cremonini F, Camilleri M, Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. Neurogastroenterol Motil 2007;19:732-43
   PubMed Web of Science ®Google Scholar
• Engel JB, Schally AV. Drug insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab 2007;3:157-67
   PubMedGoogle Scholar
• Akaza H. Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment. Pharmacology 2010;85:110-20
   PubMed Web of Science ®Google Scholar
• Hackshaw A. Luteinizing hormone-releasing hormone (LHRH) agonists in the treatment of breast cancer. Expert Opin Pharmacother 2009;10:2633-9
   PubMed Web of Science ®Google Scholar
• Rance NE, Krajewski SJ, Smith MA, Neurokinin B and the hypothalamic regulation of reproduction. Brain Res 2010;2010:116-28
   Web of Science ®Google Scholar
• Ballesteros JA, Weinstein H. Integrated methods for construction three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci 1995;25:366-428
   Google Scholar